A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome.
about
Primary immunodeficiencies associated with eosinophiliaDiscovery of single-gene inborn errors of immunity by next generation sequencingAn update on the hyper-IgE syndromesMendelian genetics of human susceptibility to fungal infectionCancers Related to Immunodeficiencies: Update and PerspectivesPrimary immunodeficiency update: Part I. Syndromes associated with eczematous dermatitisHuman TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndromeThe Hyper-IgE Syndromes: Lessons in Nature, From Bench to BedsideTYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traitsAn eMERGE Clinical Center at Partners Personalized MedicinePatterns of Allergic Sensitization in High IgE Syndromes.The molecular regulation of Janus kinase (JAK) activationUpdate on Janus kinase antagonists in inflammatory bowel disease.The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders.Inherited and acquired immunodeficiencies underlying tuberculosis in childhood.Functional STAT3 deficiency compromises the generation of human T follicular helper cells.In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activityIntestinal Epithelial Cell Tyrosine Kinase 2 Transduces IL-22 Signals To Protect from Acute Colitis.Establishing the role of tyrosine kinase 2 in cancer.Molecular mechanisms of mucocutaneous immunity against Candida and Staphylococcus species.Therapeutic targeting of the Jak/STAT pathway.ICON: the early diagnosis of congenital immunodeficiencies.Cytokine immunomodulation for the treatment of infectious diseases: lessons from primary immunodeficiencies.Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases.The JAK-STAT pathway: impact on human disease and therapeutic interventionUnraveling the Link Between Ectodermal Disorders and Primary Immunodeficiencies.Primary Immunodeficiencies with Elevated IgE.Tyrosine kinase 2 is not limiting human antiviral type III interferon responses.The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.Tyk2 is a therapeutic target for psoriasis-like skin inflammation.Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences.Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases.Mutations in the TLR3 signaling pathway and beyond in adult patients with herpes simplex encephalitis.A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors.Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance.Exome Sequencing Identifies a Novel MAP3K14 Mutation in Recessive Atypical Combined Immunodeficiency.Compound heterozygous TYK2 mutations underlie primary immunodeficiency with T-cell lymphopenia.The Role of Human IL-17 Immunity in Fungal Disease
P2860
Q26746046-AB19DC4B-4AB8-4BBA-B541-120D48C3250CQ27003187-F8920096-0B07-4F8A-8CCF-B5A7D4CBB32EQ27021598-47A24205-9C5A-401B-8736-46C5090D1DD8Q27022250-B84E6DBC-91BA-431C-A4CD-3BD121F0AB14Q28074182-55B6AEB8-7A03-4B6D-AE7C-24DB085D983BQ28086897-359CE368-D2F8-4C85-A66B-82D39A27A240Q28266613-F6BB3B15-54CA-43D3-BD00-641CA49A70B2Q28282449-4C49B255-47A4-49C4-B315-9C4F504BD59BQ28545832-277D6797-AB80-4282-90D6-850180455217Q28601813-25A084F1-1DC8-4C64-B23E-BE4B4B89AC31Q30278478-5422E973-90B6-4AE8-A752-47922A7B0442Q33956113-018A402D-03C0-4160-8464-687D5713EED1Q34030650-4A74E882-3669-496D-87E6-57150972CAE9Q34349150-5E20CA66-A920-48B3-8890-7FB4C3FEF9FDQ35510477-12F9F155-6D04-4A8D-86FB-A3D7F5A6DC2AQ35970620-34335168-FF93-4650-B856-D83404270C60Q36107965-0C345C35-1029-4007-B632-855AD97DAFD7Q36255322-10B8ACDB-2FCE-4DF4-8BC2-39D776074620Q36643671-79761167-AF48-4789-94BB-382DD0C55C2EQ36989715-91E6A22A-397A-4FD5-9807-F5710366C1F6Q38155957-6B3254D8-3411-4FEA-8C7D-3889C39C84E7Q38195246-070F04C9-7E3A-49A2-9CCD-32C0727A0213Q38216460-5B3809A3-1C0F-4B0F-A17F-2E8AD3BAB440Q38257749-18AEDF26-75DE-4DC7-800F-F36C6026504EQ38317993-8F930765-580D-4791-8CEB-C8D66C5B0405Q38379582-68A76238-B448-495D-BD11-294306EEF771Q38477275-27880463-3EDC-4105-ABCD-ABD92774CD68Q38733510-8C43C6DE-0AF8-4965-ADC4-6B23AB7AB647Q38761961-DC1B400F-8646-47F0-90E2-3BDF02CB6216Q39042555-784E8C39-BF11-4947-8AA2-9594DE80742FQ39297760-0DFB3B30-ACDC-4A41-9E20-85DE274C4FADQ39413866-21D8BF08-A5E3-417C-8B3D-CA09DB296285Q40380432-FD771CB0-BF62-41E8-8F76-F38228CC84B5Q41995656-F3C942B2-7E66-4627-B43B-337ABEEF1342Q42227306-7C6784A7-666B-45B5-8F71-8A0428627214Q46286838-9CE6F615-CF5E-4AAD-9026-FCB9D9381FB5Q54112529-1A450B9F-E5BF-4230-A4B1-27A50341AB0AQ56939724-8A0C4C3F-7C27-467E-86B1-F7F38E5B7839
P2860
A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome.
@ast
A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome.
@en
type
label
A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome.
@ast
A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome.
@en
prefLabel
A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome.
@ast
A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome.
@en
P2093
P2860
P1476
A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome.
@en
P2093
Alexandra Y Kreins
Audrey V Grant
Laurent Abel
Mustafa Hacimustafaoglu
Sara S Kilic
P2860
P304
P356
10.1016/J.JPEDS.2012.01.056
P407
P577
2012-03-07T00:00:00Z